BCIQ Profiles

Company Profile ReportTarget Profile Report

Genkyotex begins Phase II of GKT831 in PBC

Genkyotex S.A. (Euronext:GKTX) began a Phase II trial to evaluate once- and twice-daily 400 mg

Read the full 152 word article

How to gain access

Continue reading with a
two-week free trial.